Glucagon / GLP-1 receptor dual agonist (investigational)
Survodutide
Investigational dual GCGR/GLP-1R studied for obesity and liver metabolic disease.
Primary Mechanism of Action
Clinical / Scientific
Survodutide activates GLP-1 receptors (satiety, insulinotropism) and receptors (hepatic lipid oxidation / energy expenditure hypotheses) in clinical development. Not a generally labelled dual .
Pathway Targets
GLP-1 receptor
Scientific explanation
Incretin / satiety agonism.
Glucagon receptor
Scientific explanation
Metabolic energy-expenditure agonism in trials.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GLP-1 receptor → Glucagon receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GLP-1R / GCGR | Dual agonism | Weight and hepatic metabolism in development | Investigational |
In Plain Language
Survodutide is an experimental peptide that hits GLP-1 receptors and receptors together.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
GLP-1 receptor
Glucagon receptor
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.